The upcoming clinical trial for the Phantom X implantable EMG sensor system marks a significant milestone in advancing myoelectric prosthesis control for individuals with upper limb amputations. The study, sponsored by Phantom Neuro Inc., alongside Cabrini Health and ProMotion Prosthetics, will evaluate the performance of the Phantom X system in patients with below-elbow amputations, wrist disarticulations, or transradial amputations.
Scheduled to begin recruitment, this trial will provide valuable data to support the system’s safety and effectiveness, contributing to ongoing innovations in prosthetic technologies.
What is the Phantom X EMG sensor system?
The Phantom X EMG sensor array is an implantable device designed to improve the control and functionality of myoelectric prostheses. It employs a multielectrode configuration implanted within the user’s residual limb to capture high-fidelity electromyographic (EMG) signals. These signals are then used to control the movements of advanced prosthetic devices, enhancing precision and responsiveness compared to traditional systems.
Designed specifically for individuals with upper limb amputations, this technology aims to address the current limitations of external EMG sensors, such as signal variability and lower accuracy in real-world applications.
What does this clinical trial involve?
This trial will focus on individuals who have undergone upper limb amputation below the elbow, including cases of transradial amputation and wrist disarticulation. Researchers will evaluate the Phantom X system’s safety, signal stability, and effectiveness in controlling upper limb prosthetic devices. The trial will collect data to support potential regulatory submissions and broader adoption of this technology.
The study is being conducted in partnership with leading medical and prosthetic organizations, including Cabrini Health in Melbourne, Australia, and ProMotion Prosthetics. Recruitment has not yet begun, and further details about eligibility criteria and study design are forthcoming.
Why is this significant?
For the growing population of individuals with upper limb amputations, gaining intuitive and reliable control over prosthetic devices is critical for rehabilitation and quality of life. The Phantom X system represents a significant step forward in addressing this need.
By capturing EMG signals directly within the residual limb, the device seeks to deliver a more natural and precise control experience. Should this trial demonstrate positive safety and performance outcomes, it could pave the way for advances in prosthetic technology, improving accessibility and functionality for users globally.
FAQs about the trial
- Who is eligible to participate in the trial?
Individuals with upper limb amputations below the elbow, such as wrist disarticulations and transradial amputations, may qualify for this study. Further details about specific inclusion and exclusion criteria will be available upon the commencement of recruitment. - When will recruitment begin?
Recruitment for the trial has not yet started. Updates on participant enrollment timelines are expected in the near future. - What are the participating institutions?
The clinical trial is being supported by Phantom Neuro Inc., Cabrini Health in Melbourne, and ProMotion Prosthetics in Moorabbin, Australia. - What are the objectives of the trial?
The primary goals include evaluating the safety, efficacy, and functionality of the Phantom X system for myoelectric control of prostheses in real-life scenarios.
Conclusion
The Phantom X implantable EMG system trial is a promising development in the field of prosthetic innovation. By focusing on intuitive control and improved functionality, this technology has the potential to transform outcomes for individuals dealing with upper limb amputations. Clinical teams, research organizations, and regulatory authorities will be keenly observing the trial results.
Disclaimer
This article is intended for informational purposes and should not be construed as legal or clinical advice. Professionals should consult appropriate regulatory and clinical guidelines for decision-making.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07325708?term=medical+device